[go: up one dir, main page]

WO2008140598A3 - Novel immunotherapeutic mycobacteria, pharmaceutic formulations and uses thereof - Google Patents

Novel immunotherapeutic mycobacteria, pharmaceutic formulations and uses thereof Download PDF

Info

Publication number
WO2008140598A3
WO2008140598A3 PCT/US2007/086335 US2007086335W WO2008140598A3 WO 2008140598 A3 WO2008140598 A3 WO 2008140598A3 US 2007086335 W US2007086335 W US 2007086335W WO 2008140598 A3 WO2008140598 A3 WO 2008140598A3
Authority
WO
WIPO (PCT)
Prior art keywords
mycobacterium strains
mycobacteria
pharmaceutic
methods
genetically modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/086335
Other languages
French (fr)
Other versions
WO2008140598A2 (en
Inventor
David M. Hone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bacilligen Inc
Original Assignee
Bacilligen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bacilligen Inc filed Critical Bacilligen Inc
Publication of WO2008140598A2 publication Critical patent/WO2008140598A2/en
Anticipated expiration legal-status Critical
Publication of WO2008140598A3 publication Critical patent/WO2008140598A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

This invention provides genetically modified Mycobacterium strains that are useful as an anticancer immunotherapeutic. The genetically modified Mycobacterium strains preferably display at least one genetic modification resulting in increased tissue adherence, which can be combined with genetic modifications that increase immunopotency and result in adjuvant production. The invention also provides compositions and methods for the development of said Mycobacterium strains, and pharmaceutic compositions and methods for the use of said Mycobacterium strains as anticancer therapeutics.
PCT/US2007/086335 2006-12-04 2007-12-04 Novel immunotherapeutic mycobacteria, pharmaceutic formulations and uses thereof Ceased WO2008140598A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86845006P 2006-12-04 2006-12-04
US60/868,450 2006-12-04

Publications (2)

Publication Number Publication Date
WO2008140598A2 WO2008140598A2 (en) 2008-11-20
WO2008140598A3 true WO2008140598A3 (en) 2016-06-09

Family

ID=40002815

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/086335 Ceased WO2008140598A2 (en) 2006-12-04 2007-12-04 Novel immunotherapeutic mycobacteria, pharmaceutic formulations and uses thereof

Country Status (1)

Country Link
WO (1) WO2008140598A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
KR101928684B1 (en) * 2009-01-08 2018-12-12 앨버트 아인슈타인 컬리지 오브 메디신, 인크. Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
US12359209B2 (en) 2018-04-17 2025-07-15 The Johns Hopkins Unversity Recombinant therapeutic interventions for cancer
CN112601535A (en) * 2018-04-17 2021-04-02 约翰霍普金斯大学 Recombinant therapeutic intervention for cancer
EP4317441A4 (en) * 2021-03-22 2025-09-17 Clipsbnc Co Ltd New recombinant strain of Mycobacterium smegmatis and use thereof
CN118715022A (en) * 2022-02-11 2024-09-27 布坦坦研究所 Compositions comprising recombinant mycobacterium strains, uses thereof and methods for preventing and/or treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050220811A1 (en) * 2002-04-05 2005-10-06 Stewart Cole Identification of virulence associated regions rd1 and rd5 leading to improve vaccine of m. bovis bcg and m. microti
EP1882741A1 (en) * 2006-07-25 2008-01-30 Institut Pasteur Recombinant Mycobacterium strain expressing a mycobacterial FAP protein under the control of a promoter active under hypoxia and its application for cancer therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050220811A1 (en) * 2002-04-05 2005-10-06 Stewart Cole Identification of virulence associated regions rd1 and rd5 leading to improve vaccine of m. bovis bcg and m. microti
EP1882741A1 (en) * 2006-07-25 2008-01-30 Institut Pasteur Recombinant Mycobacterium strain expressing a mycobacterial FAP protein under the control of a promoter active under hypoxia and its application for cancer therapy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
LEWIS ET AL.: "Deletion of RD1 from Mycobacterium tuberculosis Mimics Bacille Calmette-Guerin Attenuation.", JOURNAL OF INFECTIOUS DISEASES, vol. 187, no. 1, 2003, pages 117 - 23, XP002987276, DOI: doi:10.1086/345862 *
MIYAMOTO ET AL.: "Aggregation of mycobacteria caused by disruption of fibronectin-attachment protein-encoding gene .", FEMS MICROBIOLOGY LETTERS, vol. 236, no. 2, 2004, pages 227 - 234 *
SECOTT ET AL.: "Fibronectin Attachment Protein Is Necessary for Efficient Attachment and Invasion of Epithelial Cells by Mycobacterium avium subsp. paratuberculosis.", INFECTION AND IMMUNITY, vol. 70, no. 5, May 2002 (2002-05-01), pages 2670 - 2675 *
ZHAO ET AL.: "Characterization of the Fibronectin Binding Motif for a Unique Mycobacterial Fibronectin Attachment Protein, FAP.", J. BIOL CHEM, vol. 274, no. 8, 19 February 1999 (1999-02-19), pages 4521 - 4526 *
ZHAO ET AL.: "ROLE OF A BACILLUS CALMETTE-GUERIN FIBRONECTIN ATTACHMENT PROTEIN IN BCG-INDUCED ANTITUMOR ACTIVITY.", INT. J. CANCER, vol. 86, no. 1, 2000, pages 83 - 88, XP002401487, DOI: doi:10.1002/(SICI)1097-0215(20000401)86:1<83::AID-IJC13>3.0.CO;2-R *

Also Published As

Publication number Publication date
WO2008140598A2 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
WO2008140598A3 (en) Novel immunotherapeutic mycobacteria, pharmaceutic formulations and uses thereof
WO2010144344A3 (en) Melanocortin receptor-specific peptides
WO2010078457A3 (en) Methods of producing isoprene and a co-product
MX2010004244A (en) Organic compounds.
EP3444352A3 (en) Production of recombinant vaccine in e. coli by enzymatic conjugation
EP2698412A3 (en) Mesogen containing compounds
WO2006120208A8 (en) Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
EP2537857A3 (en) Mutant forms of streptolysin O
AU2016204319A1 (en) Methods and compositions for producing squalene using yeast
MA35803B1 (en) Interleukin-2 mutant polypeptides
EP4218802A3 (en) Conjugates for targeted cell surface editing
CY1118065T1 (en) INNOVATIVE AMINOGLYCOSIDES AND THEIR USES IN THE TREATMENT OF GENETIC DISORDERS
WO2008049758A3 (en) Disperse dyes, their preparation and their use
ZA200903903B (en) Crystalline solid rasagiline base
WO2011008495A3 (en) Arginase formulations and methods
WO2007016093A3 (en) Peroxide removal from drug delivery vehicle
JO2831B1 (en) Quinuclidine Carbonate Derivatives and Medicinal Composition Thereof
WO2009042114A3 (en) Phenazine derivatives and uses thereof
WO2008109142A3 (en) Pirna and uses related thereto
WO2010115751A3 (en) Oxadiazole derivatives
MX2010003200A (en) Stable imatinib compositions.
WO2007021937A3 (en) Unsaturated heterocyclic derivatives
WO2009007535A3 (en) Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics
WO2010132112A3 (en) Immunogenic compositions against tuberculosis
WO2009035959A3 (en) Radiofluorination methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07874337

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07874337

Country of ref document: EP

Kind code of ref document: A2